63 results about "Renal Cell Cancers" patented technology

The present disclosure relates to detecting one or more types of urinary system cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of urinary system cancer (e.g., urothelial carcinoma and / or renal cell carcinoma) in a biological sample from a subject suffering from or suspected of suffering from urinary system cancer.

This disclosure is directed to two cancer-associated fibroblast (CAP) subtypes, namely permissive (permCAF) and restraining (restCAF), in pancreatic ductal adenocarcinoma (PDAC), mesothelioma, urothelial carcinoma, or renal cell carcinoma. Methods are disclosed that describe how to identify a tumor sample as a perCAF or a restCAF subtypes. Methods are also disclosed that use the subtypes for diagnosis, prognosis, differential treatment, and treatment.

The invention relates to the technical field of biotechnology or biomedical engineering, in particular to hydrogel, bio-ink, organoids constructed by using the hydrogel, a drug screening model and a construction method. The hydrogel is prepared from 3 to 4 weight percent of gelatin, 0.5 to 2 weight percent of sodium alginate, 20 to 40 weight percent of matrigel and a cell culture medium. The hydrogel is helpful for improving the bionic degree of a tumor microenvironment, can be used for preparing bio-ink containing target cells such as tumor cells, particularly can be used for preparing bio-ink of primary cells (such as primary renal cell carcinoma cells), and an organ-like model constructed by using the bio-ink under a proper 3D biological printing condition is uniform in growth and high in biocompatibility. The cell growth speed is high, the consistency with parent tissues is high, the in-vitro amplification time of the patient-derived tumor cells can be shortened, the influence of subculture factors on the cell affinity can be reduced, the drug development progress can be accelerated, and the production cost can be reduced.

The present invention provides a method for preparing and using a CD70-specific diagnostic-integrated molecular imaging probe, which comprises a tumor targeting group and a radionuclide, the tumor targeting group being selected from a CD70-specific nanobody or a CD70-specific nanobody fusion protein, the CD70-specific nanobody being B3 or B6 having the amino acid sequences set forth in SEQ ID NO. 1 and SEQ ID NO. 3, and the CD70-specific nanobody fusion protein being ABDB3 or ABDB6 having the amino acid sequences set forth in SEQ ID NO. 5 and SEQ ID NO. 7. The present invention achieves noninvasive visualization of human CD70 molecule expression and realizes noninvasive diagnosis of renal cell carcinoma. This probe has the advantages of simple preparation, low cost, high specificity, high stability, short imaging cycle, low radiation dose, and easy clinical translation.

The application discloses an HLA-A*11:01 renal cell carcinoma tumor antigen short peptide derived from a long-chain non-coding RNA SLC12A5-AS1 and application thereof. The application provides a tumor antigen peptide, and an amino acid sequence of the tumor antigen peptide is shown as SEQ ID No. 1. It is found by the application that a complex formed by the short peptide and a corresponding HLA molecule (HLA-A*11:01) can be recognized by T cells, and an immune response is activated. The application provides a potential target for renal cell carcinoma treatment, and provides a new target screening direction for subsequent tumor antigen treatment of renal cell carcinoma.

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The invention relates to the technical field of diagnosis, in particular to a prognosis evaluation kit and evaluation method for renal cell carcinoma patients based on DNAJA1 protein expression quantity. The method for evaluating the prognosis and immune microenvironment state of the RCC patient based on the DNAJA1 expression level provided by the invention has good stability, accuracy and operability, can realize hierarchical management and individualized treatment guidance of patient risks, and has remarkable clinical and social values.

The present invention relates to a biomarker for diagnosing renal cell carcinoma and a use thereof. The biomarker specifically increases or decreases in expression in renal cell carcinoma patients compared to a normal group and can thus be used for monitoring, diagnosing, and predicting the prognosis of renal cell carcinoma. In particular, the biomarker can be effectively used for the early diagnosis of renal cell carcinoma.

The application discloses a kind of kidney cell cancer patient prognosis risk prediction methods based on multi-modal deep learning.The present application processes whole field digital pathology section (WSI) image and pathological diagnosis report by deep learning algorithm, extracts text features using natural language processing model, extracts image features using computer vision model and ABMIL network, and carries out multi-modal feature fusion through Cross-attention Transformer network, and finally outputs the survival risk curve of patient changes with time in combination with Weibull survival function, for assisting doctor to carry out more accurate prognosis evaluation and survival analysis.

A system, computer readable medium, apparatus and / or method for non-invasive, non-surgical, digital biopsy. The system, computer readable medium, apparatus and / or method accurately predicts benign kidney lesions from cancers in a patient. A processor may receive patient clinical factors, texture analysis of computer-tomographic imaging, and an artificial intelligence learning model. By implementing artificial intelligence, the processor may then predict or determine a probability of kidney cancer in the patient using the patient clinical factors, the texture analysis of computer-tomographic imaging, and the artificial intelligence learning model. Notably, the prediction is performed without needing invasive biopsy surgery and subsequent pathology analysis to arrive at a diagnosis but relies on radiomics metrics.

The presently disclosed subject matter provides cells, compositions, and methods for enhancing immune responses to tumor antigens. These cells comprise a first antigen-recognizing receptor that targets CD70. These cells have improved activity and / or efficiency. The present invention also provides a method for reducing tumor burden in a subject with renal cell carcinoma, pancreatic cancer, or ovarian cancer, comprising administering to the subject an effective amount of cells comprising a TCR-like fusion molecule that targets CD70.

The invention relates to a novel cyclopeptide medicine PT-C10 with anti-tumor activity. The amino acid sequence of the novel cyclopeptide medicine PT-C10 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C10 to the 786-O kidney cancer cells is 42.23 mu M, and the IC50 of the cyclopeptide PT-C10 to the A498 kidney cancer cells is 15.53 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and the A498 and shows obvious killing efficacy. The cyclic peptide PT-C10 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

Disclosed herein are novel compounds that are Mpsl / TTK inhibitors. Also disclosed are compositions comprising the compounds and methods of using the compounds in treating various diseases. In some embodiments, some such compounds, compositions, and their uses may be useful for the treatment of cancer. In some implementations, the cancer is brain cancer, glioblastoma multiforme, head and neck cancers, colorectal cancer, stomach or gastric cancer, pancreatic cancer, melanoma, bladder cancer, kidney cancer, renal cell carcinoma, breast cancer, ovarian cancer, lymphoma, thyroid cancer, mesothelioma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, or endometrial cancer.

The invention relates to a novel cyclopeptide drug PT-C07 with antitumor activity. The amino acid sequence of the novel cyclopeptide drug PT-C07 is shown as SEQ ID NO: 1. The cyclic peptide has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a preparation method of the cyclopeptide through microwave-promoted Fmoc protection solid-phase synthesis, and an application of the cyclopeptide in preparation of antitumor drugs. Experimental results show that the IC50 of the cyclopeptide PT-C07 to the 786-O kidney cancer cells is 77.53 mu M, and the IC50 of the cyclopeptide PT-C07 to the A498 kidney cancer cells is 67.06 mu M, so that the cyclopeptide PT-C07 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The cyclic peptide PT-C07 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The present disclosure relates to the detection of one or more types of urological cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of urological cancer (e.g., urothelial carcinoma and / or renal cell carcinoma) in a biological sample from a subject having or suspected of having urological cancer.

This invention belongs to the field of image classification technology, specifically relating to a method for predicting sinus invasion of renal cell carcinoma based on prior information. The method includes: acquiring CT images; constructing a renal cell carcinoma sinus invasion prediction dataset based on the CT images; extracting features from the data in the dataset; constructing a heterogeneous graph based on the extracted feature maps; inputting the heterogeneous graph into a trained prior-driven graph neural network model to obtain the renal cell carcinoma sinus invasion prediction result; and evaluating the prediction result. This invention generates different potential appearances in a data-driven manner through a diffusion perturbation strategy and learns perturbation-invariant features, thereby correcting for the network performance degradation caused by cross-dataset applications.

The present technology provides compounds, as well as compositions including such compounds, useful for imaging and / or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and / or a prostate cancer.

The invention belongs to the field of chemical synthesis, and particularly relates to a small molecule compound K-H03 with an anti-tumor effect and application of the small molecule compound K-H03 in anti-tumor drugs, and the small molecule compound has a structural formula as shown in a formula I. The compound has a good killing effect on renal cell carcinoma cells and is suitable for treating renal cell carcinoma. The invention also provides a method for preparing the compound and application of the compound in preparation of antitumor drugs. Experimental results show that the IC50 of the K-H03 to the 786-O kidney cancer cells is 203.0 [mu] M, and the IC50 of the K-H03 to the A498 kidney cancer cells is 175.5 [mu] M, which indicates that the K-H03 can obviously reduce the cell viability of the 786-O and A498 and shows obvious killing efficacy. The K-H03 provides a new treatment strategy for patients with renal cell carcinoma, and is expected to improve the treatment effect and the life quality of the patients.

The invention discloses a renal cell carcinoma circulating tumor cell culture medium as well as a culture method and application thereof. The invention belongs to the field of biological medicine, and particularly relates to a renal cell carcinoma circulating tumor cell culture medium and a culture method and application. The invention provides a composition for culturing circulating tumor cells, the composition contains a cell culture medium and a biological scaffold, the cell culture medium contains a reagent named as RFGI, and the RFGI contains fetal calf serum, insulin, glucose and R-spondin-1 protein. Enriching the isolated circulating tumor cells through density gradient centrifugation; the composition is used for culturing the enriched circulating tumor cells to obtain the circulating tumor cells, so that the survival rate of the circulating tumor cells is effectively improved, and the composition has huge potential and application prospects for subsequent drug screening.

The invention relates to a novel liposome polydopamine nanoparticle and application thereof in treating renal cell carcinoma. The preparation method of the nanoparticles comprises the following steps: adding liposome into si-circPVT1 dissolved in ribonuclease-free water, and carrying out vortex mixing to form a si-circPVT1 liposome suspension; dispersing the dopamine PDA modified liposome into a Tris-HCl solution, then adding dopamine hydrochloride, and stirring to obtain dopamine PDA modified liposome; then dispersing in a streptavidin solution, and fully oscillating at 4 DEG C under a dark condition to obtain a compound; and mixing the complex with a biotin-labeled MUC12 antibody solution for incubation, and washing the obtained suspension with a PBS (Phosphate Buffer Solution) to obtain the novel liposome polydopamine nanoparticles marked as SCLPM-NPs. The product prepared by the invention realizes targeted delivery of kidney cell cancer cell lines, and the SCLPM-NPs can effectively target tumor tissue parts and inhibit the growth of kidney tumors.

A method for performing in vivo imaging or detection of cancer in a subject in need thereof, the method comprising: - administering to the subject an agent for binding to CAIX expressed by the cancer, wherein the agent comprises a detectable moiety for enabling in vivo detection of the agent in the subject; and - detecting the agent in the subject, wherein the cancer is not renal cell carcinoma.

The application discloses an HLA-A*11:01 renal cell carcinoma tumor antigen short peptide derived from a long-chain non-coding RNA LINC02717. The application provides a tumor antigen peptide, and the amino acid sequence of the tumor antigen peptide is shown as SEQ ID No. 1. The application finds that the complex formed by the short peptide and a corresponding HLA molecule (HLA-A*11:01) can be recognized by T cells, and an immune response is activated. The application provides a potential target for renal cell carcinoma treatment, and provides a new target screening direction for subsequent tumor antigen treatment of renal cell carcinoma.

The present invention relates to the use of soluble CD27 as a biomarker to predict response to immune checkpoint inhibitor treatment. The inventors have collaborated with two queues of patients and have identified a soluble marker CD27 present in the plasma of renal cell carcinoma patients, the pre-treatment concentration of which can predict a response against PD-1 / PD-L1. The marker is more like a predictive marker of response to anti-PD-1 / PD-L1 therapy, rather than as a prognostic marker. In fact, it is independent of a better survival rate of metastatic renal cell carcinoma patients receiving treatment with anti-angiogenic agents. The markers are not associated with conventional clinical severity markers that classify metastatic kidney cancer patients.

The invention discloses an application of sanguinarine chloride (SGC) in preparation of a medicine for treating a PRCC-TFE3 rearranged renal cell carcinoma (rRCC), and belongs to the technical field of biological medicine, in particular to an application of sanguinarine chloride (SGC) in preparation of a medicine for treating a PRCC-TFE3 rearranged renal cell carcinoma (rRCC). According to the application, it is found for the first time that SGC has a specific killing effect on PRCC-TFE3 rRCC cells and has extremely low toxicity on normal kidney cells; the SGC has multiple anti-tumor action mechanisms: on one hand, the SGC is directly combined with and antagonizes a VEGFR2 receptor on a cell membrane to block autocrine signal transduction of VEGFB; on the other hand, the SGC inhibits transcription of VEGFB (vascular endothelial growth factor B) through ROS / p-STAT3 axis epigenetics; besides, the SGC can inhibit the production of lactic acid and the acylation of H3K18, and down-regulate the secretion of chemotactic factors, so that the infiltration of polymorphic myeloid-derived suppressor cells (PMN-MDSCs) in a tumor microenvironment is remarkably inhibited; in an immune sound mouse model, the SGC shows an excellent in-vivo anti-tumor effect, and a brand new targeting and immunoregulation double-effect candidate drug is provided for clinically treating the PRCC-TFE3 rRCC lacking an effective standard therapy.

The invention relates to the technical field of crossing of medical image analysis and gene detection, in particular to a construction method of a cell-level pathological feature and gene mutation data matching model, the cell-level pathological feature and gene mutation data matching model and application of the cell-level pathological feature and gene mutation data matching model. According to the method, high-resolution pathological image analysis and single-cell gene mutation sequencing technologies are combined, so that cell-level pathological feature extraction of the pathological image and accurate correlation analysis of gene mutation are realized, the accuracy and comprehensiveness of pathological diagnosis are improved, richer focus information is provided for clinicians, and the clinical application prospect is wide. The method has the advantages that a more personalized treatment scheme can be formulated, a new way is further developed for precise medical treatment of the renal cell carcinoma by comprehensively analyzing pathological characteristics such as cell morphology, nucleolus characteristics and chromatin distribution and gene mutation data, and the method has important clinical application value and social significance.

The present application belongs to the technical field of biological medicine, and relates to a gene therapy preparation for treating drug-resistant renal cell carcinoma as well as a preparation method and application thereof. It is found for the first time that UBL3 is a key gene for mediating cross-resistance of VEGFR inhibitors of renal cancer, and a lipid nanoparticle composite system integrating specific gene editing and active targeted delivery functions is constructed based on this. The preparation can effectively restore the sensitivity of drug-resistant tumors to first-line drugs such as sunitinib, and shows a significant anticancer effect in in-vivo and in-vitro models, and has important clinical transformation value.

There is provided a compound according to formula (I), or a pharmaceutically acceptable salt or prodrug thereof.

The invention relates to the technical field of diagnosis, in particular to application of S100A11 as a biomarker in preparation of a renal cell carcinoma prognosis evaluation kit, the renal cell carcinoma patient prognosis evaluation kit and an evaluation method. The invention provides a method for evaluating the prognosis and immune microenvironment state of a patient with renal cell carcinoma (RCC) based on the expression level of S100A11, which has good stability, accuracy and operability, can realize hierarchical management and individualized treatment guidance of patient risks, and has remarkable clinical and social values.

The invention belongs to the technical field of biological medicines, and particularly relates to application of GLRX5 in preparation of a medicine for enhancing immunotherapy of renal cell carcinoma. GLRX5 is a tumor inhibition factor in renal cell carcinoma and a key factor for regulating and controlling the stability of renal cell carcinoma PD-L1, can inhibit proliferation and metastasis of renal carcinoma, specifically interacts with PD-L1, and inhibits immune escape of renal carcinoma by enhancing SPOP-mediated PD-L1 K48 connection ubiquitination and proteasome degradation, so that treatment of an immunosuppressor is enhanced; the molecular mechanism determines that the GLRX5 is used as a key coordination factor of an SPOP-PD-L1 degradation axis in a renal cell carcinoma pathogenesis, also reveals that the GLRX5-SPOP-PD-L1 axis is a key mechanism of RCC immune escape, and provides a new strategy for promoting PD-L1 degradation and reversing immunosuppression by enhancing the expression or activity of the GLRX5.

The present invention relates to methods and compositions for the treatment of BAF-related disorders such as melanoma, prostate cancer, breast cancer, bone cancer, renal cell carcinoma, and hematologic cancer.